Loading stock data…
Nautilus Biotechnology (NAUT)
$1.79-0.21 (-10.50%)
Market ClosedLast close Jun 29
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nautilus Biotechnology, Inc. in the Healthcare sector is trading at $1.79 with a market capitalization of $281M. Wall Street consensus targets $4.00 (1 analysts), implying a +123.5% move over the next 12 months. The stock is currently 58% below its 52-week high of $4.31, remaining 16.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +123.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 24) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.12M↓ | -$15.42M↑ | -$15.47M↑ | -$17.10M↑ | -$18.84M |
| Net Income | -$14.70M↓ | -$13.78M↓ | -$13.57M↑ | -$15.03M↑ | -$16.61M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, whic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$281.48M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.53%
Volume
Today's trading volume
2.09M
Recent News
3 Penny Stocks With Market Caps Over $100M To Watch
The market is up 1.2% over the last week, and in the past year, it has climbed an impressive 27%, with earnings expected to grow by 17% per annum. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still present significant opportunities when built on solid financials. We've identified three penny stocks that demonstrate financial strength and potential for growth, offering investors a chance to uncover hidden value in quality...
3 Promising Penny Stocks With Market Caps Up To $900M
The market remained flat over the last week, yet it is up 28% over the past year with earnings expected to grow by 16% per annum in the coming years. In this context, identifying stocks that combine solid financials with growth potential is crucial for investors looking to capitalize on market opportunities. Penny stocks, often associated with smaller or newer companies, continue to be relevant as they can offer significant returns when backed by strong fundamentals.
Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Nautilus Biotechnology Inc (NAUT) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
Nautilus Biotechnology Inc (NAUT) reports decreased operating expenses and strategic progress towards commercialization, despite revenue recognition challenges.
Nautilus Biotechnology Q1 Earnings Call Highlights
Nautilus Biotechnology (NASDAQ:NAUT) reported first-quarter 2026 results and highlighted progress toward its planned commercialization timeline, with management emphasizing expanding early customer engagement, advancing its assay portfolio, and maintaining what it described as a cash runway through